Home » Clinical Trials » Search Clinical Trials
Parent Therapeutic Areas: Oncology
Non-Hodgkin's Lymphoma
A Phase 2 study comparing rituximab plus sargramostim to rituximab monotherapy for treatment of relapsed, follicular B-cell lymphoma.
A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)
A Phase 2 study comparing rituximab plus sargramostim to rituximab monotherapy for treatment of relapsed, follicular B-cell lymphoma.
A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)
A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)
A Phase 2 study comparing rituximab plus sargramostim to rituximab monotherapy for treatment of relapsed, follicular B-cell lymphoma.
Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
A Phase 2 study comparing rituximab plus sargramostim to rituximab monotherapy for treatment of relapsed, follicular B-cell lymphoma.
A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)
Study Comparing the Zevalin Regimen With No Further Treatment in DLBCL Patients Who Are in Complete Remission After CHOP-R
Study Comparing the Zevalin Regimen With No Further Treatment in DLBCL Patients Who Are in Complete Remission After CHOP-R
A Phase 2 study comparing rituximab plus sargramostim to rituximab monotherapy for treatment of relapsed, follicular B-cell lymphoma.
Study Comparing the Zevalin Regimen With No Further Treatment in DLBCL Patients Who Are in Complete Remission After CHOP-R
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
A Phase 1B Study to Evaluate the Safety and Tolerability of AMG 655 in Combination with Bortezomib or Vorinostat in Subjects with Relapsed or Refractory Lymphoma
A Phase I Study of De-Immunized DI-Leu16-IL2 Immunocytokine in Patients with B-Cell Non-Hodgkin’s Lymphoma
A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for B–Cell Non–Hodgkin Lymphoma Using Zevalin®, Fludarabine and Melphalan
A Phase II Study of Vorinstat (Suberoylanilide Hydroaxamic Acid)Plus Rituximab in Indolent Non-Hodgkin's Lymphoma
A Phase II Study of Yttrium-90-Labeled Anti-CD20 Monoclonal Antibody in Combination with High-Dose Beam (BCNU, Etoposide, Cytarabine and Melphalan) Followed by Autologous Stem Cell Transplantation for Patients with Poor Risk/Relapsed B-Cell Lymphoma
A Pilot Study of Safety and Feasibility of Stem Cell Therapy for Aids Lymphoma Using Stem Cells Treated with a Lentivirus Vector-Encoding Multiple Anti-HIV RNAs
An Open-Label , Single-Arm Phase II Study of RAD001 in Patients with Refractory Mantle Cell Lymphoma
Genetic Epidemiology of Non-Hodgkin's Lymphoma (NHL)
High Dose Chemotherapy and Combination anti-HIV Therapy for HIV-Associated Hodgkin's and Non-Hodgkin's Lymphoma
Long-Term Follow Up of Recipients of Gene Transfer Research at City of Hope
Multicenter Evaluation of Non-Hodgkins Lymphoma patterns and Outcomes of Care Within the National Comprehensive Cancer Network (NCCN)
Obtaining Leukapheresed Peripheral Blood Mononuclear Cells from Mantle Cell Lymphoma Patients in Remission for Use in T Cell Program
PHI-58 NCI# 7943:Phase I Study of GX15-070 (NSC #729280) and Bortezomib in Aggressive Relapsed/Recurrent Non-Hodgkin's Lymphoma
SWOG S0350: Phase II Trial of Cisplatin Plus Etoposide Plus Gemcitabine Plus Solumedrol (Pegs) in Peripheral T-Cell Non-Hodgkin's Lymphoma
SWOG S0433: Iodine-131 Labeled Monoclonal Antibody (I-131 Tositumomab) in Combination with Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, and Rituximab Therapy for Patients With Advanced Stage Diffuse Large B Cell NHL; A Phase II Study
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
A Phase 2 study comparing rituximab plus sargramostim to rituximab monotherapy for treatment of relapsed, follicular B-cell lymphoma.
A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)
A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)
A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)
A Dose-Escalating Study of R7159 Monotherapy in Patients With CD20+ Malignant Disease.
A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)
A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)
A Phase 2 study comparing rituximab plus sargramostim to rituximab monotherapy for treatment of relapsed, follicular B-cell lymphoma.
A Dose-Escalating Study of R7159 Monotherapy in Patients With CD20+ Malignant Disease.
A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)
Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
A Phase 2 study comparing rituximab plus sargramostim to rituximab monotherapy for treatment of relapsed, follicular B-cell lymphoma.
Study Comparing the Zevalin Regimen With No Further Treatment in DLBCL Patients Who Are in Complete Remission After CHOP-R
A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)
A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)
A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
Study Comparing the Zevalin Regimen With No Further Treatment in DLBCL Patients Who Are in Complete Remission After CHOP-R
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
A Dose-Escalating Study of R7159 Monotherapy in Patients With CD20+ Malignant Disease.
A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)
Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)
A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
A Dose-Escalating Study of R7159 Monotherapy in Patients With CD20+ Malignant Disease.
A Phase 2 study comparing rituximab plus sargramostim to rituximab monotherapy for treatment of relapsed, follicular B-cell lymphoma.
A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)
Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals
A Phase 2 study comparing rituximab plus sargramostim to rituximab monotherapy for treatment of relapsed, follicular B-cell lymphoma.
A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)
A Phase 2 study comparing rituximab plus sargramostim to rituximab monotherapy for treatment of relapsed, follicular B-cell lymphoma.
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
A Phase 2 study comparing rituximab plus sargramostim to rituximab monotherapy for treatment of relapsed, follicular B-cell lymphoma.
A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)
A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)
Study Comparing the Zevalin Regimen With No Further Treatment in DLBCL Patients Who Are in Complete Remission After CHOP-R
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
A Dose-Escalating Study of R7159 Monotherapy in Patients With CD20+ Malignant Disease.
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
A Dose-Escalating Study of R7159 Monotherapy in Patients With CD20+ Malignant Disease.
A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)
A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)
Study Comparing the Zevalin Regimen With No Further Treatment in DLBCL Patients Who Are in Complete Remission After CHOP-R
A Dose-Escalating Study of R7159 Monotherapy in Patients With CD20+ Malignant Disease.
Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals
Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)
A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)
Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals
Study Comparing the Zevalin Regimen With No Further Treatment in DLBCL Patients Who Are in Complete Remission After CHOP-R
A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)
A Phase 2 study comparing rituximab plus sargramostim to rituximab monotherapy for treatment of relapsed, follicular B-cell lymphoma.
A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)
A Phase 2 study comparing rituximab plus sargramostim to rituximab monotherapy for treatment of relapsed, follicular B-cell lymphoma.
Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL)
Study of HCD122 in Adults With Non-Hodgkin's or Hodgkin's Lymphoma Who Have Progressed After at Least Two Prior Therapies
A Phase 2 study comparing rituximab plus sargramostim to rituximab monotherapy for treatment of relapsed, follicular B-cell lymphoma.
A Phase 2 study comparing rituximab plus sargramostim to rituximab monotherapy for treatment of relapsed, follicular B-cell lymphoma.
A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)
A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
Study Comparing the Zevalin Regimen With No Further Treatment in DLBCL Patients Who Are in Complete Remission After CHOP-R
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)
A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)
A Phase 2 study comparing rituximab plus sargramostim to rituximab monotherapy for treatment of relapsed, follicular B-cell lymphoma.
A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)
A Phase 2 study comparing rituximab plus sargramostim to rituximab monotherapy for treatment of relapsed, follicular B-cell lymphoma.
A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)
A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)
A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)
A Dose-Escalating Study of R7159 Monotherapy in Patients With CD20+ Malignant Disease.
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
Study Comparing the Zevalin Regimen With No Further Treatment in DLBCL Patients Who Are in Complete Remission After CHOP-R
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)
A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
Study Comparing the Zevalin Regimen With No Further Treatment in DLBCL Patients Who Are in Complete Remission After CHOP-R
A Phase 2 study comparing rituximab plus sargramostim to rituximab monotherapy for treatment of relapsed, follicular B-cell lymphoma.
A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)
A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)
A Phase 2 study comparing rituximab plus sargramostim to rituximab monotherapy for treatment of relapsed, follicular B-cell lymphoma.
A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)
A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)
A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)
A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)
A Dose-Escalating Study of R7159 Monotherapy in Patients With CD20+ Malignant Disease.
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
A Phase 2 study comparing rituximab plus sargramostim to rituximab monotherapy for treatment of relapsed, follicular B-cell lymphoma.
Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals
A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
A Phase 2 study comparing rituximab plus sargramostim to rituximab monotherapy for treatment of relapsed, follicular B-cell lymphoma.
A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)
Study Comparing the Zevalin Regimen With No Further Treatment in DLBCL Patients Who Are in Complete Remission After CHOP-R
Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals
A Phase 2 study comparing rituximab plus sargramostim to rituximab monotherapy for treatment of relapsed, follicular B-cell lymphoma.
A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia (CLL) Adults
A Dose-Escalating Study of R7159 Monotherapy in Patients With CD20+ Malignant Disease.
A Phase 2 study comparing rituximab plus sargramostim to rituximab monotherapy for treatment of relapsed, follicular B-cell lymphoma.
An Open-label Phase II/III Study of Rituximab in Combination With Recombinant Human IL-2 for Relapsed Low-grade or Follicular Non-Hodgkin's Lymphoma in Patients Who Have Previously Failed Rituximab
An Open-labeled, Phase 2 Study of Rituximab in Combination With Recombinant Human IL-2 for Relapsed or Refractory Non-Hodgkin's Lymphoma of Intermediate or High-grade Histology
Phase III Randomized Trial of CHOP Chemotherapy with or without Rituximab (Chimeric Anti CD Antibody) for HIV Associated Non-Hodgkin's Lymphoma
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
This is a phase II study in which patients will receive uniform doses of fludarabine and rituximab for low-grade lymphoma and chronic lymphocytic leukemia, and for responding patients who can tolerate it, CAMPATH will be given only during the final 2 months of treatment on this study.
A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
A Dose-Escalating Study of R7159 Monotherapy in Patients With CD20+ Malignant Disease.
Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals
A Phase 2 study comparing rituximab plus sargramostim to rituximab monotherapy for treatment of relapsed, follicular B-cell lymphoma.
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)
A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)
A Dose-Escalating Study of R7159 Monotherapy in Patients With CD20+ Malignant Disease.
A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)
A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)
A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)
A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)
A Dose-Escalating Study of R7159 Monotherapy in Patients With CD20+ Malignant Disease.
A Phase 2 study comparing rituximab plus sargramostim to rituximab monotherapy for treatment of relapsed, follicular B-cell lymphoma.
A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)
A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)
A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)
A Phase 2 study comparing rituximab plus sargramostim to rituximab monotherapy for treatment of relapsed, follicular B-cell lymphoma.
A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
A Dose-Escalating Study of R7159 Monotherapy in Patients With CD20+ Malignant Disease.
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)
A Phase 2 study comparing rituximab plus sargramostim to rituximab monotherapy for treatment of relapsed, follicular B-cell lymphoma.
A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)
A Dose-Escalating Study of R7159 Monotherapy in Patients With CD20+ Malignant Disease.
Study Comparing the Zevalin Regimen With No Further Treatment in DLBCL Patients Who Are in Complete Remission After CHOP-R
A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)
Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals
A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)
A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)
A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)
A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)
A Phase 2 study comparing rituximab plus sargramostim to rituximab monotherapy for treatment of relapsed, follicular B-cell lymphoma.
A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)
A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)
A Phase 2 study comparing rituximab plus sargramostim to rituximab monotherapy for treatment of relapsed, follicular B-cell lymphoma.
A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
A Dose-Escalating Study of R7159 Monotherapy in Patients With CD20+ Malignant Disease.
A Phase 2 study comparing rituximab plus sargramostim to rituximab monotherapy for treatment of relapsed, follicular B-cell lymphoma.
Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals
Phase II Study Of Antineoplaston A10 And AS2-1 In Patients With Non-Hodgkin’s Lymphoma Intermediate Grade
Phase II Study Of Antineoplaston A10 And AS2-1 In Patients With Non-Hodgkin’s Lymphoma, Low Grade
Phase II Study Of Antineoplaston A10 And AS2-1 In Patients With Non-Hodgkin's Lymphoma, High Grade
Phase II Study Of Antineoplastons A10 And AS2-1 In Patients With Non-Hodgkin’s Lymphoma
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
A Dose-Escalating Study of R7159 Monotherapy in Patients With CD20+ Malignant Disease.
A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)
A Dose-Escalating Study of R7159 Monotherapy in Patients With CD20+ Malignant Disease.
Adults with Non-Hodgkins Lymphoma Sought for a Research Study.
Study Comparing the Zevalin Regimen With No Further Treatment in DLBCL Patients Who Are in Complete Remission After CHOP-R
A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)
A Dose-Escalating Study of R7159 Monotherapy in Patients With CD20+ Malignant Disease.
Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
A Dose-Escalating Study of R7159 Monotherapy in Patients With CD20+ Malignant Disease.
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
A Study of RO5072759 in Combination With Chemotherapy in Patients With CD20+ B-Cell Follicular Non-Hodgkin's Lymphoma
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
A Study of Ocrelizumab in Patients With Follicular Non-Hodgkin's Lymphoma (NHL)
A Study of RO5072759 in Combination With Chemotherapy in Patients With CD20+ B-Cell Follicular Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
A Study of RO5072759 in Combination With Chemotherapy in Patients With CD20+ B-Cell Follicular Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
A Study of Ocrelizumab in Patients With Follicular Non-Hodgkin's Lymphoma (NHL)
A Study of RO5072759 in Combination With Chemotherapy in Patients With CD20+ B-Cell Follicular Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma
A Dose-Escalating Study of R7159 Monotherapy in Patients With CD20+ Malignant Disease.
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma
A Dose-Escalating Study of R7159 Monotherapy in Patients With CD20+ Malignant Disease.
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
A Dose-Escalating Study of R7159 Monotherapy in Patients With CD20+ Malignant Disease.
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) in Patients With HIV-Related Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
A Dose-Escalating Study of R7159 Monotherapy in Patients With CD20+ Malignant Disease.
A Dose-Escalating Study of R7159 Monotherapy in Patients With CD20+ Malignant Disease.
A Dose-Escalating Study of R7159 Monotherapy in Patients With CD20+ Malignant Disease.
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
A Dose-Escalating Study of R7159 Monotherapy in Patients With CD20+ Malignant Disease.
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma
A Dose-Escalating Study of R7159 Monotherapy in Patients With CD20+ Malignant Disease.
A Dose-Escalating Study of R7159 Monotherapy in Patients With CD20+ Malignant Disease.
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
A Dose-Escalating Study of R7159 Monotherapy in Patients With CD20+ Malignant Disease.
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma
A Dose-Escalating Study of R7159 Monotherapy in Patients With CD20+ Malignant Disease.
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma
A Dose-Escalating Study of R7159 Monotherapy in Patients With CD20+ Malignant Disease.
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
A Dose-Escalating Study of R7159 Monotherapy in Patients With CD20+ Malignant Disease.
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
A Dose-Escalating Study of R7159 Monotherapy in Patients With CD20+ Malignant Disease.
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
A Dose-Escalating Study of R7159 Monotherapy in Patients With CD20+ Malignant Disease.
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
A Dose-Escalating Study of R7159 Monotherapy in Patients With CD20+ Malignant Disease.
A Study of Ocrelizumab in Patients With Follicular Non-Hodgkin's Lymphoma (NHL)
A Dose-Escalating Study of R7159 Monotherapy in Patients With CD20+ Malignant Disease.
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma
An Expanded Access Program of Neulastim (Pegfilgrastim)in Patients With Non-Hodgkin's Lymphoma
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
A Dose-Escalating Study of R7159 Monotherapy in Patients With CD20+ Malignant Disease.
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma
A Dose-Escalating Study of R7159 Monotherapy in Patients With CD20+ Malignant Disease.
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
A Dose-Escalating Study of R7159 Monotherapy in Patients With CD20+ Malignant Disease.
A Dose-Escalating Study of R7159 Monotherapy in Patients With CD20+ Malignant Disease.
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
A Study of MabThera (Rituximab) in Patients With Non-Bulky Follicular Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) in Patients With Non-Bulky Follicular Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) in Patients With Non-Bulky Follicular Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) in Patients With Non-Bulky Follicular Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) in Patients With Non-Bulky Follicular Non-Hodgkin's Lymphoma
A Study of Ocrelizumab in Patients With Follicular Non-Hodgkin's Lymphoma (NHL)
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) in Patients With Non-Bulky Follicular Non-Hodgkin's Lymphoma
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
A Study of Ocrelizumab in Patients With Follicular Non-Hodgkin's Lymphoma (NHL)
A Study of RO5072759 in Combination With Chemotherapy in Patients With CD20+ B-Cell Follicular Non-Hodgkin's Lymphoma
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
A Study of MabThera (Rituximab) in Patients With Non-Bulky Follicular Non-Hodgkin's Lymphoma
A Study of RO5072759 in Combination With Chemotherapy in Patients With CD20+ B-Cell Follicular Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) in Patients With Non-Bulky Follicular Non-Hodgkin's Lymphoma
A Study of Ocrelizumab in Patients With Follicular Non-Hodgkin's Lymphoma (NHL)
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) in Patients With Non-Bulky Follicular Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) in Patients With Non-Bulky Follicular Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) in Patients With Non-Bulky Follicular Non-Hodgkin's Lymphoma
A Study of Ocrelizumab in Patients With Follicular Non-Hodgkin's Lymphoma (NHL)
A Study of RO5072759 in Combination With Chemotherapy in Patients With CD20+ B-Cell Follicular Non-Hodgkin's Lymphoma
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
A Study of MabThera (Rituximab) in Patients With Non-Bulky Follicular Non-Hodgkin's Lymphoma
A Study of Ocrelizumab in Patients With Follicular Non-Hodgkin's Lymphoma (NHL)
A Study of MabThera (Rituximab) in Patients With Non-Bulky Follicular Non-Hodgkin's Lymphoma
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) in Patients With Non-Bulky Follicular Non-Hodgkin's Lymphoma
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
A Study of MabThera (Rituximab) in Patients With Non-Bulky Follicular Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) in Patients With Advanced Non-Hodgkin's Lymphoma
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
A Study of MabThera (Rituximab) in Patients With Advanced Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) in Patients With Advanced Non-Hodgkin's Lymphoma
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
A Study of MabThera (Rituximab) in Patients With Advanced Non-Hodgkin's Lymphoma
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
A Study of MabThera (Rituximab) in Patients With Advanced Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) in Patients With Advanced Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) in Patients With Advanced Non-Hodgkin's Lymphoma
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
A Study of MabThera (Rituximab) in Patients With Advanced Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) in Patients With Advanced Non-Hodgkin's Lymphoma
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) in Patients With Advanced Non-Hodgkin's Lymphoma
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) in Patients With Advanced Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) in Patients With Relapsed Centroblastic Centrocytic Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) in Patients With Advanced Non-Hodgkin's Lymphoma
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) in Patients With Advanced Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) in Patients With Advanced Non-Hodgkin's Lymphoma
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
A Study of RO5072759 in Combination With Chemotherapy in Patients With CD20+ B-Cell Follicular Non-Hodgkin's Lymphoma
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
A Study of RO5072759 in Combination With Chemotherapy in Patients With CD20+ B-Cell Follicular Non-Hodgkin's Lymphoma
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) in Patients With Advanced Non-Hodgkin's Lymphoma
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) in Patients With Advanced Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) in Patients With Advanced Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
A Study of RO5072759 in Combination With Chemotherapy in Patients With CD20+ B-Cell Follicular Non-Hodgkin's Lymphoma
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
A Study of MabThera (Rituximab) in Patients With Advanced Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) in Patients With Advanced Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
A Study of MabThera (Rituximab) in Patients With Advanced Non-Hodgkin's Lymphoma
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) in Patients With Advanced Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) in Patients With Advanced Non-Hodgkin's Lymphoma
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
A Study of MabThera (Rituximab) in Patients With Advanced Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) in Patients With Advanced Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) in Patients With Advanced Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
A Study of MabThera (Rituximab) in Patients With Advanced Non-Hodgkin's Lymphoma
A Dose-Escalating Study of R7159 Monotherapy in Patients With CD20+ Malignant Disease.
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
A Dose-Escalating Study of R7159 Monotherapy in Patients With CD20+ Malignant Disease.
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
A Study of MabThera (Rituximab) in Elderly Patients With Untreated Follicular Non-Hodgkin's Lymphoma (NHL)
A Study of MabThera (Rituximab) in Elderly Patients With Untreated Follicular Non-Hodgkin's Lymphoma (NHL)
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
A Study of MabThera (Rituximab) in Elderly Patients With Untreated Follicular Non-Hodgkin's Lymphoma (NHL)
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
A Study of MabThera (Rituximab) in Elderly Patients With Untreated Follicular Non-Hodgkin's Lymphoma (NHL)
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
A Study of MabThera (Rituximab) in Elderly Patients With Untreated Follicular Non-Hodgkin's Lymphoma (NHL)
A Dose-Escalating Study of R7159 Monotherapy in Patients With CD20+ Malignant Disease.
A Study of MabThera (Rituximab) in Elderly Patients With Untreated Follicular Non-Hodgkin's Lymphoma (NHL)
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
A Study of MabThera (Rituximab) in Elderly Patients With Untreated Follicular Non-Hodgkin's Lymphoma (NHL)
A Dose-Escalating Study of R7159 Monotherapy in Patients With CD20+ Malignant Disease.
A Study of Induction and Maintenance Treatment With MabThera (Rituximab) in Patients With Indolent B-Cell Nonfollicular Lymphomas
A Study of MabThera (Rituximab) in Elderly Patients With Untreated Follicular Non-Hodgkin's Lymphoma (NHL)
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
A Study of MabThera (Rituximab) in Elderly Patients With Untreated Follicular Non-Hodgkin's Lymphoma (NHL)
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
A Study of MabThera (Rituximab) in Elderly Patients With Untreated Follicular Non-Hodgkin's Lymphoma (NHL)
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
A Study of MabThera (Rituximab) in Elderly Patients With Untreated Follicular Non-Hodgkin's Lymphoma (NHL)
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
A Study of MabThera (Rituximab) in Elderly Patients With Untreated Follicular Non-Hodgkin's Lymphoma (NHL)
A Study of MabThera (Rituximab) in Elderly Patients With Untreated Follicular Non-Hodgkin's Lymphoma (NHL)
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
A Study of Induction and Maintenance Treatment With MabThera (Rituximab) in Patients With Indolent B-Cell Nonfollicular Lymphomas
A Study of MabThera (Rituximab) in Elderly Patients With Untreated Follicular Non-Hodgkin's Lymphoma (NHL)
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
A Study of Induction and Maintenance Treatment With MabThera (Rituximab) in Patients With Indolent B-Cell Nonfollicular Lymphomas
A Study of MabThera (Rituximab) in Elderly Patients With Untreated Follicular Non-Hodgkin's Lymphoma (NHL)
A Dose-Escalating Study of R7159 Monotherapy in Patients With CD20+ Malignant Disease.
A Study of Induction and Maintenance Treatment With MabThera (Rituximab) in Patients With Indolent B-Cell Nonfollicular Lymphomas
A Study of MabThera (Rituximab) in Elderly Patients With Untreated Follicular Non-Hodgkin's Lymphoma (NHL)
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
A Study of MabThera (Rituximab) in Elderly Patients With Untreated Follicular Non-Hodgkin's Lymphoma (NHL)
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) in Elderly Patients With Untreated Follicular Non-Hodgkin's Lymphoma (NHL)
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
A Study of MabThera (Rituximab) in Elderly Patients With Untreated Follicular Non-Hodgkin's Lymphoma (NHL)
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
A Study of MabThera (Rituximab) in Elderly Patients With Untreated Follicular Non-Hodgkin's Lymphoma (NHL)
A Dose-Escalating Study of R7159 Monotherapy in Patients With CD20+ Malignant Disease.
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
A Study of MabThera (Rituximab) in Elderly Patients With Untreated Follicular Non-Hodgkin's Lymphoma (NHL)
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
A Study of MabThera (Rituximab) in Elderly Patients With Untreated Follicular Non-Hodgkin's Lymphoma (NHL)
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
A Study of MabThera (Rituximab) in Elderly Patients With Untreated Follicular Non-Hodgkin's Lymphoma (NHL)
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
A Study of MabThera (Rituximab) in Elderly Patients With Untreated Follicular Non-Hodgkin's Lymphoma (NHL)
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
A Study of MabThera (Rituximab) in Elderly Patients With Untreated Follicular Non-Hodgkin's Lymphoma (NHL)
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
A Study of MabThera (Rituximab) in Elderly Patients With Untreated Follicular Non-Hodgkin's Lymphoma (NHL)
A Dose-Escalating Study of R7159 Monotherapy in Patients With CD20+ Malignant Disease.
A Study of MabThera (Rituximab) in Elderly Patients With Untreated Follicular Non-Hodgkin's Lymphoma (NHL)
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
A Study of MabThera (Rituximab) in Elderly Patients With Untreated Follicular Non-Hodgkin's Lymphoma (NHL)
A Dose-Escalating Study of R7159 Monotherapy in Patients With CD20+ Malignant Disease.
A Study of Induction and Maintenance Treatment With MabThera (Rituximab) in Patients With Indolent B-Cell Nonfollicular Lymphomas
A Study of MabThera (Rituximab) in Elderly Patients With Untreated Follicular Non-Hodgkin's Lymphoma (NHL)
A Study of Induction and Maintenance Treatment With MabThera (Rituximab) in Patients With Indolent B-Cell Nonfollicular Lymphomas
A Study of MabThera (Rituximab) in Elderly Patients With Untreated Follicular Non-Hodgkin's Lymphoma (NHL)
A Study of Induction and Maintenance Treatment With MabThera (Rituximab) in Patients With Indolent B-Cell Nonfollicular Lymphomas
A Study of Induction and Maintenance Treatment With MabThera (Rituximab) in Patients With Indolent B-Cell Nonfollicular Lymphomas
A Study of MabThera (Rituximab) in Elderly Patients With Untreated Follicular Non-Hodgkin's Lymphoma (NHL)
A Study of Ocrelizumab in Patients With Follicular Non-Hodgkin's Lymphoma (NHL)
A Study of RO5072759 in Combination With Chemotherapy in Patients With CD20+ B-Cell Follicular Non-Hodgkin's Lymphoma
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
A Dose-Escalating Study of R7159 Monotherapy in Patients With CD20+ Malignant Disease.
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
A Study of Induction and Maintenance Treatment With MabThera (Rituximab) in Patients With Indolent B-Cell Nonfollicular Lymphomas
A Study of MabThera (Rituximab) in Elderly Patients With Untreated Follicular Non-Hodgkin's Lymphoma (NHL)
A Study of Ocrelizumab in Patients With Follicular Non-Hodgkin's Lymphoma (NHL)
A Study of RO5072759 in Combination With Chemotherapy in Patients With CD20+ B-Cell Follicular Non-Hodgkin's Lymphoma
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
A Study of MabThera (Rituximab) in Elderly Patients With Untreated Follicular Non-Hodgkin's Lymphoma (NHL)
A Study of MabThera (Rituximab) in Elderly Patients With Untreated Follicular Non-Hodgkin's Lymphoma (NHL)
A Study of MabThera (Rituximab) in Elderly Patients With Untreated Follicular Non-Hodgkin's Lymphoma (NHL)
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma
An Expanded Access Program of Neulastim (Pegfilgrastim)in Patients With Non-Hodgkin's Lymphoma
An Expanded Access Program of Neulastim (Pegfilgrastim)in Patients With Non-Hodgkin's Lymphoma
An Expanded Access Program of Neulastim (Pegfilgrastim)in Patients With Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma
An Expanded Access Program of Neulastim (Pegfilgrastim)in Patients With Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma
An Expanded Access Program of Neulastim (Pegfilgrastim)in Patients With Non-Hodgkin's Lymphoma
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma
An Expanded Access Program of Neulastim (Pegfilgrastim)in Patients With Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma
An Expanded Access Program of Neulastim (Pegfilgrastim)in Patients With Non-Hodgkin's Lymphoma
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
An Expanded Access Program of Neulastim (Pegfilgrastim)in Patients With Non-Hodgkin's Lymphoma
A Dose-Escalating Study of R7159 Monotherapy in Patients With CD20+ Malignant Disease.
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
A Dose-Escalating Study of R7159 Monotherapy in Patients With CD20+ Malignant Disease.
A Dose-Escalating Study of R7159 Monotherapy in Patients With CD20+ Malignant Disease.
A Dose-Escalating Study of R7159 Monotherapy in Patients With CD20+ Malignant Disease.
A Dose-Escalating Study of R7159 Monotherapy in Patients With CD20+ Malignant Disease.
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
A Dose-Escalating Study of R7159 Monotherapy in Patients With CD20+ Malignant Disease.
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
A Dose-Escalating Study of R7159 Monotherapy in Patients With CD20+ Malignant Disease.
A Study of RO5072759 in Combination With Chemotherapy in Patients With CD20+ B-Cell Follicular Non-Hodgkin's Lymphoma
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
A Dose-Escalating Study of R7159 Monotherapy in Patients With CD20+ Malignant Disease.
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
A Dose-Escalating Study of R7159 Monotherapy in Patients With CD20+ Malignant Disease.
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
A Dose-Escalating Study of R7159 Monotherapy in Patients With CD20+ Malignant Disease.
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
A Dose-Escalating Study of R7159 Monotherapy in Patients With CD20+ Malignant Disease.
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
A Dose-Escalating Study of R7159 Monotherapy in Patients With CD20+ Malignant Disease.
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
A Dose-Escalating Study of R7159 Monotherapy in Patients With CD20+ Malignant Disease.
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
A Dose-Escalating Study of R7159 Monotherapy in Patients With CD20+ Malignant Disease.
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
A Study of Ocrelizumab in Patients With Follicular Non-Hodgkin's Lymphoma (NHL)
A Dose-Escalating Study of R7159 Monotherapy in Patients With CD20+ Malignant Disease.
A Study of Ocrelizumab in Patients With Follicular Non-Hodgkin's Lymphoma (NHL)
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
A Study of Ocrelizumab in Patients With Follicular Non-Hodgkin's Lymphoma (NHL)
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
A Study of Ocrelizumab in Patients With Follicular Non-Hodgkin's Lymphoma (NHL)
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
A Dose-Escalating Study of R7159 Monotherapy in Patients With CD20+ Malignant Disease.
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
A Dose-Escalating Study of R7159 Monotherapy in Patients With CD20+ Malignant Disease.
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma
A Dose-Escalating Study of R7159 Monotherapy in Patients With CD20+ Malignant Disease.
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
A Dose-Escalating Study of R7159 Monotherapy in Patients With CD20+ Malignant Disease.
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
A Study of RO5072759 in Combination With Chemotherapy in Patients With CD20+ B-Cell Follicular Non-Hodgkin's Lymphoma
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
A Study of RO5072759 in Combination With Chemotherapy in Patients With CD20+ B-Cell Follicular Non-Hodgkin's Lymphoma
A Study of RO5072759 in Combination With Chemotherapy in Patients With CD20+ B-Cell Follicular Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
A Study of RO5072759 in Combination With Chemotherapy in Patients With CD20+ B-Cell Follicular Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
A Study of RO5072759 in Combination With Chemotherapy in Patients With CD20+ B-Cell Follicular Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
A Dose-Escalating Study of R7159 Monotherapy in Patients With CD20+ Malignant Disease.
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
